Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Efinopegdutide in Metabolic Dysfunction Associated Steatohepatitis: NCT04944992 Clinical Landscape Report 2026
16 October 2026
NCT04944992 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Nitrofurazone in Amyotrophic Lateral Sclerosis: NCT04950647 Clinical Landscape Report 2026
16 October 2026
NCT04950647 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Reldesemtiv in Amyotrophic Lateral Sclerosis: NCT04944784 Clinical Landscape Report 2026
16 October 2026
NCT04944784 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Satralizumab in Myasthenia Gravis: NCT04963270 Clinical Landscape Report 2026
16 October 2026
NCT04963270 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fosigotifator in Amyotrophic Lateral Sclerosis: NCT04948645 Clinical Landscape Report 2026
16 October 2026
NCT04948645 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lansoprazole in Idiopathic Pulmonary Fibrosis: NCT04965298 Clinical Landscape Report 2026
16 October 2026
NCT04965298 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nipocalimab-aahu in Myasthenia Gravis: NCT04951622 Clinical Landscape Report 2026
16 October 2026
NCT04951622 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Taladegib in Idiopathic Pulmonary Fibrosis: NCT04968574 Clinical Landscape Report 2026
16 October 2026
NCT04968574 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Semaglutide (Novo Nordisk) in Metabolic Dysfunction Associated Steatohepatitis: NCT04971785 Clinical Landscape Report 2026
16 October 2026
NCT04971785 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Osivelotor in Anemia, Sickle Cell: NCT04983264 Clinical Landscape Report 2026
16 October 2026
NCT04983264 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atorvastatin Calcium in Metabolic Dysfunction Associated Steatohepatitis: NCT04972396 Clinical Landscape Report 2026
16 October 2026
NCT04972396 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Flupenthixol Hydrochloride/Melitracen Hydrochloride in Alzheimer Disease: NCT04970667 Clinical Landscape Report 2026
16 October 2026
NCT04970667 clinical landscape for Alzheimer Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.